Loading
A phase 1/2 trial of Nivolumab in advanced solid tumours, run by BicycleTx Limited, active and no longer recruiting.
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression is a phase 1/2 interventional study registered as NCT05163041 by BicycleTx Limited, with 200 participants enrolled, started 2021-11-02 and due to reach its primary completion in 2026-08. Interventions recorded: BT7480 and Nivolumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Bicycle Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bicycle Therapeutics and the tag pipeline.
Shares Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/